BML-190

BML-190
IUPAC ime
	2-[1-(4-hlorobenzoil)-5-metoksi-2-metilindol-3-il]-1-morfolin-4-iletanon
Identifikatori
CAS broj	2854-32-2
ATC kod	none
PubChem	CID 2415
ChemSpider	2321
Hemijski podaci
Formula	C23H23ClN2O4
Molarna masa	426,892
	SMILES C4COCCN4C(=O)Cc(c(c1cc2)cc2OC)c(C)n1C(=O)c3ccc(Cl)cc3; ;
	InChI InChI=1S/C23H23ClN2O4/c1-15-19(14-22(27)25-9-11-30-12-10-25)20-13-18(29-2)7-8-21(20)26(15)23(28)16-3-5-17(24)6-4-16/h3-8,13H,9-12,14H2,1-2H3 ; Key:BJSDNVVWJYDOLK-UHFFFAOYSA-N ;

BML-190 (Indometacin morfolinilamid) je lek koji se koristi u naučnim istraživanjima. On deluje kao selektivan inverzni agonist CB₂ receptora.^[1] BML-190 je strukturni analog NSAID indometacina koji ima sasvim različita biološka svojstava.^[2] Neki izvori osporavaju aktivnost ovoj jedinjenja, i navode da je CB₂ agonist umesto inverznog agonista.^[3]^[4] Razlog za to može da bude greška u klasifikaciji, ili alternativno moguće je da ovaj materijal proizvodi različite efekte u različitim tkivima i eksperimentalnim uslovima.

Reference уреди

^ New, DC; Wong, YH (2003). „BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates”. FEBS Letters. 536 (1–3): 157—60. PMID 12586356. doi:10.1016/S0014-5793(03)00048-6.
^ Klegeris, A; Bissonnette, CJ; McGeer, PL (2003). „Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor”. British Journal of Pharmacology. 139 (4): 775—86. PMC 1573900  . PMID 12813001. doi:10.1038/sj.bjp.0705304.
^ Melck, D; De Petrocellis, L; Orlando, P; Bisogno, T; Laezza, C; Bifulco, M; Di Marzo, V (2000). „Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation”. Endocrinology. 141 (1): 118—26. PMID 10614630. doi:10.1210/en.141.1.118.
^ Scutt, A; Williamson, EM (2007). „Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors”. Calcified tissue international. 80 (1): 50—9. PMID 17205329. doi:10.1007/s00223-006-0171-7.

Spoljašnje veze уреди

[1] New, DC; Wong, YH (2003). „BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates”. FEBS Letters. 536 (1–3): 157—60. PMID 12586356. doi:10.1016/S0014-5793(03)00048-6.

[2] Klegeris, A; Bissonnette, CJ; McGeer, PL (2003). „Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor”. British Journal of Pharmacology. 139 (4): 775—86. PMC 1573900  . PMID 12813001. doi:10.1038/sj.bjp.0705304.

[3] Melck, D; De Petrocellis, L; Orlando, P; Bisogno, T; Laezza, C; Bifulco, M; Di Marzo, V (2000). „Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation”. Endocrinology. 141 (1): 118—26. PMID 10614630. doi:10.1210/en.141.1.118.

[4] Scutt, A; Williamson, EM (2007). „Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors”. Calcified tissue international. 80 (1): 50—9. PMID 17205329. doi:10.1007/s00223-006-0171-7.

[1]

[2]

[3]

[4]